CRBU · Caribou Biosciences Inc. Common Stock
View on chartInsiders & Stakes
| Barbara G. McClung Chief Legal Officer | ▼ Sell | Open Market | 481,564 Shares held | 2/24/2026 | View profile |
| Rachel E. Haurwitz Director | ▲ Buy | Grant | 447,150 Shares held | 2/20/2026 | View profile |
| Steven Kanner Chief Scientific Officer | ▼ Sell | Open Market | 431,556 Shares held | 2/21/2025 | View profile |
| Ryan Fischesser VP of Finance and Controller | ▲ Buy | Grant | 118,854 Shares held | 11/20/2024 | View profile |
| Ruhi Ahmad Khan Chief Business Officer | ▼ Sell | Open Market | 104,998 Shares held | 2/24/2026 | View profile |
| Timothy P. Kelly See Remarks. | ▼ Sell | Open Market | 73,125 Shares held | 2/25/2026 | View profile |
| Sriram Ryali Chief Financial Officer | ▲ Buy | Grant | 72,360 Shares held | 2/20/2026 | View profile |
| Tina M. Albertson Chief Medical Officer | ▼ Sell | Open Market | 68,523 Shares held | 2/24/2026 | View profile |
| Syed Ali-aamir Rizvi Chief Medical Officer | ▼ Sell | Open Market | 59,373 Shares held | 1/19/2023 | View profile |
| Jason O'Byrne EVP & Chief Financial Officer | ▲ Buy | Grant | 59,224 Shares held | 2/20/2024 | View profile |
Transaction History
| Timothy P. Kelly | ▼ Sell | Open Market | 6,228 | $12K | 2/25/2026 |
| Timothy P. Kelly | ▼ Sell | Open Market | 3,147 | $6K | 2/24/2026 |
| Barbara G. McClung | ▼ Sell | Open Market | 6,938 | $14K | 2/24/2026 |
| Ruhi Ahmad Khan | ▼ Sell | Open Market | 6,938 | $14K | 2/24/2026 |
| Tina M. Albertson | ▼ Sell | Open Market | 1,066 | $2K | 2/24/2026 |
| Timothy P. Kelly | ▲ Buy | Grant | 45,000 | $0 | 2/20/2026 |
| Barbara G. McClung | ▲ Buy | Grant | 45,000 | $0 | 2/20/2026 |
| Ruhi Ahmad Khan | ▲ Buy | Grant | 45,000 | $0 | 2/20/2026 |
| Tina M. Albertson | ▲ Buy | Grant | 55,000 | $0 | 2/20/2026 |
| Sriram Ryali | ▲ Buy | Grant | 55,000 | $0 | 2/20/2026 |
| Rachel E. Haurwitz | ▲ Buy | Grant | 151,700 | $0 | 2/20/2026 |
| Rachel E. Haurwitz | ▲ Buy | Open Market | 20,000 | $20K | 3/14/2025 |
| Barbara G. McClung | ▼ Sell | Open Market | 3,564 | $5K | 2/21/2025 |
| Ruhi Ahmad Khan | ▼ Sell | Open Market | 3,564 | $5K | 2/21/2025 |
| Steven Kanner | ▼ Sell | Open Market | 3,564 | $5K | 2/21/2025 |
| Rachel E. Haurwitz | ▲ Buy | Grant | 136,750 | $0 | 2/20/2025 |
| Tina M. Albertson | ▲ Buy | Grant | 14,589 | $0 | 2/20/2025 |
| Barbara G. McClung | ▲ Buy | Grant | 37,500 | $0 | 2/20/2025 |
| Ruhi Ahmad Khan | ▲ Buy | Grant | 37,500 | $0 | 2/20/2025 |
| Timothy P. Kelly | ▲ Buy | Grant | 37,500 | $0 | 2/20/2025 |
| Steven Kanner | ▲ Buy | Grant | 37,500 | $0 | 2/20/2025 |
| Sriram Ryali | ▲ Buy | Open Market | 17,360 | $25K | 1/29/2025 |
| Ryan Fischesser | ▲ Buy | Grant | 25,000 | $0 | 11/20/2024 |
| Jason O'Byrne | ▲ Buy | Grant | 33,000 | $0 | 2/20/2024 |
| Barbara G. McClung | ▲ Buy | Grant | 33,000 | $0 | 2/20/2024 |
| Ruhi Ahmad Khan | ▲ Buy | Grant | 33,000 | $0 | 2/20/2024 |
| Rachel E. Haurwitz | ▲ Buy | Grant | 118,700 | $0 | 2/20/2024 |
| Steven Kanner | ▲ Buy | Grant | 33,000 | $0 | 2/20/2024 |
| Steven Kanner | ▲ Buy | Option Exercise | 30,577 | $82K | 2/6/2024 |
| Rachel E. Haurwitz | ▲ Buy | Option Exercise | 10,000 | $30K | 6/8/2023 |
| Rachel E. Haurwitz | ▲ Buy | Option Exercise | 10,000 | $30K | 3/20/2023 |
| Syed Ali-aamir Rizvi | ▼ Sell | Open Market | 5,627 | $36K | 1/19/2023 |
| Steven Kanner | ▲ Buy | Option Exercise | 21,401 | $58K | 12/2/2022 |
| Ryan Fischesser | ▼ Sell | Open Market | 10,000 | $108K | 10/6/2022 |
| Ryan Fischesser | ▲ Buy | Option Exercise | 2,839 | $8K | 10/6/2022 |
| Ryan Fischesser | ▲ Buy | Option Exercise | 2,839 | $12K | 10/6/2022 |
| Barbara G. McClung | ▲ Buy | Option Exercise | 77 | $207 | 9/15/2022 |
| Barbara G. McClung | ▲ Buy | Option Exercise | 27,518 | $74K | 9/15/2022 |
| Steven Kanner | ▲ Buy | Option Exercise | 43,248 | $116K | 8/25/2022 |
| Steven Kanner | ▼ Sell | Open Market | 43,248 | $485K | 8/25/2022 |
| Ryan Fischesser | ▲ Buy | Grant | 4,848 | $0 | 8/22/2022 |
| Steven Kanner | ▲ Buy | Option Exercise | 68,306 | $124K | 5/13/2022 |
| Steven Kanner | ▲ Buy | Option Exercise | 6,114 | $16K | 5/13/2022 |
| Rachel E. Haurwitz | ▲ Buy | Option Exercise | 10,000 | $30K | 5/9/2022 |
| Ryan Fischesser | ▲ Buy | Option Exercise | 1,136 | $3K | 5/5/2022 |
| Ryan Fischesser | ▲ Buy | Option Exercise | 1,138 | $5K | 5/5/2022 |
| Ryan Fischesser | ▲ Buy | Option Exercise | 1,136 | $3K | 3/15/2022 |
| Ryan Fischesser | ▲ Buy | Option Exercise | 1,138 | $5K | 3/15/2022 |
| Steven Kanner | ▲ Buy | Option Exercise | 9,171 | $25K | 3/4/2022 |
| Steven Kanner | ▲ Buy | Option Exercise | 1,549 | $6K | 3/4/2022 |
| Jason O'Byrne | ▲ Buy | Option Exercise | 24,336 | $100K | 2/8/2022 |
| Rachel E. Haurwitz | ▲ Buy | Option Exercise | 10,000 | $30K | 1/26/2022 |
| Syed Ali-aamir Rizvi | ▲ Buy | Grant | 60,000 | $0 | 1/25/2022 |
| Ryan Fischesser | ▲ Buy | Open Market | 569 | $2K | 1/11/2022 |
| Ryan Fischesser | ▲ Buy | Open Market | 6,818 | $28K | 1/11/2022 |
| Ryan Fischesser | ▲ Buy | Open Market | 1,136 | $3K | 12/20/2021 |
| Barbara G. McClung | ▲ Buy | Open Market | 12 | $32 | 12/7/2021 |
| Barbara G. McClung | ▲ Buy | Open Market | 6,115 | $16K | 12/7/2021 |
| Barbara G. McClung | ▲ Buy | Open Market | 43 | $116 | 10/20/2021 |
| Barbara G. McClung | ▲ Buy | Open Market | 9,176 | $25K | 10/20/2021 |
| Steven Kanner | ▲ Buy | Open Market | 99,548 | $180K | 10/12/2021 |
| Steven Kanner | ▲ Buy | Open Market | 14,614 | $39K | 10/12/2021 |
| Steven Kanner | ▲ Buy | Open Market | 698 | $1K | 10/12/2021 |
| Ryan Fischesser | ▲ Buy | Open Market | 1,746 | $5K | 10/11/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
No recent news for Caribou Biosciences (CRBU)
There are no recent news releases specifically about Caribou Biosciences in the past week. The stock remains unchanged in terms of public announcements. Technical indicators show RSI at 35.1 and support around $1.59, but without new information the market context is limited.
No recent news for Caribou Biosciences (CRBU). There are no recent news releases specifically about Caribou Biosciences in the past week. The stock remains unchanged in terms of public announcements. Technical indicators show RSI at 35.1 and support around $1.59, but without new information the market context is limited.